Zacks: Sesen Bio Inc (SESN) Receives Average Rating of “Strong Buy” from Analysts
Shares of Sesen Bio Inc (NASDAQ:SESN) have been given an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.
Analysts have set a 1-year consensus price target of $3.50 for the company and are anticipating that the company will post ($0.07) EPS for the current quarter, according to Zacks. Zacks has also assigned Sesen Bio an industry rank of 79 out of 255 based on the ratings given to its competitors.
Several research firms have recently weighed in on SESN. Zacks Investment Research lowered shares of Sesen Bio from a “buy” rating to a “hold” rating in a report on Tuesday, September 25th. Canaccord Genuity initiated coverage on shares of Sesen Bio in a report on Monday, July 9th. They issued a “buy” rating for the company. Finally, Jefferies Financial Group initiated coverage on shares of Sesen Bio in a report on Monday, July 23rd. They issued a “buy” rating and a $4.00 price target for the company.
NASDAQ SESN opened at $1.75 on Thursday. The company has a market cap of $165.57 million, a PE ratio of -1.58 and a beta of 2.60. Sesen Bio has a 1-year low of $0.62 and a 1-year high of $3.50.
Sesen Bio (NASDAQ:SESN) last posted its quarterly earnings data on Tuesday, August 14th. The company reported ($0.16) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.03). Equities research analysts forecast that Sesen Bio will post -0.39 EPS for the current year.
Sesen Bio Company Profile
Sesen Bio, Inc, a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer.
Read More: Fundamental Analysis and Choosing Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sesen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sesen Bio and related companies with MarketBeat.com's FREE daily email newsletter.